Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among the...
-д хадгалсан:
| Үндсэн зохиолчид: | , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
MDPI AG
2023-04-01
|
| Цуврал: | Pharmaceuticals |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.mdpi.com/1424-8247/16/4/590 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|